Back to Search Start Over

Simulation Training to Improve Informed Consent and Pharmacokinetic/Pharmacodynamic Sampling in Pediatric Trials

Authors :
Bjoern B. Burckhardt
Agnes Maria Ciplea
Anna Laven
László Ablonczy
Ingrid Klingmann
Stephanie Läer
Karl Kleine
Michiel Dalinghaus
Milan Đukić
Johannes M. P. J. Breur
Marijke van der Meulen
Vanessa Swoboda
Holger Schwender
Florian B. Lagler
Pediatrics
Source :
Frontiers in Pharmacology, Frontiers in Pharmacology, Vol 11 (2020), Frontiers in Pharmacology, 11:603042. Frontiers Media S.A.
Publication Year :
2020
Publisher :
Frontiers Media SA, 2020.

Abstract

Background: Pediatric trials to add missing data for evidence-based pharmacotherapy are still scarce. A tailored training concept appears to be a promising tool to cope with critical and complex situations before enrolling the very first patient and subsequently to ensure high-quality study conduct. The aim was to facilitate study success by optimizing the preparedness of the study staff shift.Method: An interdisciplinary faculty developed a simulation training focusing on the communication within the informed consent procedure and the conduct of the complex pharmacokinetic/pharmacodynamic (PK/PD) sampling within a simulation facility. Scenarios were video-debriefed by an audio-video system and manikins with artificial blood simulating patients were used. The training was evaluated by participants' self-assessment before and during trial recruitment.Results: The simulation training identified different optimization potentials for improved informed consent process and study conduct. It facilitated the reduction of avoidable errors, especially in the early phase of a clinical study. The knowledge gained through the intervention was used to train the study teams, improve the team composition and optimize the on-ward setting for the FP-7 funded “LENA” project (grant agreement no. 602295). Self-perceived ability to communicate core elements of the trial as well as its correct performance of sample preparation increased significantly (mean, 95% CI, p ≤ 0.0001) from 3 (2.5–3.5) to four points (4.0–4.5), and from 2 (1.5–2.5) to five points (4.0–5.0).Conclusion: An innovative training concept to optimize the informed consent process and study conduct was successfully developed and enabled high-quality conduct of the pediatric trials as of the very first patient visit.

Details

ISSN :
16639812
Volume :
11
Database :
OpenAIRE
Journal :
Frontiers in Pharmacology
Accession number :
edsair.doi.dedup.....ea8d810619242f5a91c8f73c125c5e36
Full Text :
https://doi.org/10.3389/fphar.2020.603042